BioNTech SE (BNTX) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
BioNTech SE (BNTX) Earnings Overview
As of June 28, 2026, BioNTech SE (BNTX) reported trailing twelve-month net income of -$1.26B, reflecting -62.8% year-over-year growth. The company earned $-4.97 per diluted share over the past four quarters, with a net profit margin of -39.6%.
Looking at the long-term picture, BNTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.29B in fiscal 2021.
BioNTech SE is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$3.19B net income, -145.2% margin), PFE ($7.49B net income, 12.4% margin), NVAX (-$88M net income, 39.2% margin), BNTX has outperformed on profitability metrics. Compare BNTX vs MRNA →
BNTX Earnings vs Peers
Earnings metrics vs comparable public companies
BNTX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.09B | -64.0% | -$624M | $-4.51 | -39.6% | -22.6% |
| 2024 | -$665M | -171.5% | -$1.31B | $-2.77 | -24.2% | -47.8% |
| 2023 | $930M | -90.1% | $690M | $3.83 | 24.4% | 18.1% |
| 2022 | $9.43B | -8.3% | $12.64B | $37.09 | 54.5% | 73.0% |
| 2021 | $10.29B | +67613.8% | $15.28B | $41.21 | 54.2% | 80.5% |
| 2020 | $15M | +108.5% | -$82M | $0.06 | 3.2% | -17.1% |
| 2019 | -$179M | -273.0% | -$182M | $-0.85 | -164.9% | -167.1% |
| 2018 | -$48M | +43.9% | -$54M | $-0.21 | -37.6% | -42.2% |
| 2017 | -$86M | - | -$61M | $-0.38 | -139.1% | -99.5% |
Download Data
Export BNTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BNTX — Frequently Asked Questions
Quick answers to the most common questions about buying BNTX stock.
What is BNTX earnings per share (EPS)?
BNTX trailing twelve-month (TTM) diluted EPS is $-4.97, reflecting -62.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is BioNTech SE's net income?
BioNTech SE (BNTX) trailing twelve-month net income is $-1.3B as of 2025. Earnings declined -62.8% year-over-year.
Is BNTX profitable?
BNTX is not currently profitable on a TTM basis, reporting a net loss of $-1.3B. Net margin is -39.6%. Investors should monitor for a return to profitability.
What is BNTX's earnings growth rate?
BNTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are BNTX's profit margins?
BioNTech SE net profit margin is -39.6%, operating margin is -22.6%, and gross margin is +77.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -5.7%.
Is BNTX growing earnings?
BNTX earnings are declining — EPS fell -62.8% year-over-year. TTM net income dropped to $-1.3B. This contrasts with the 5-year CAGR of N/A.
What was BNTX's best earnings year?
BioNTech SE's highest annual net income on record is $10.3B, achieved in fiscal year 2021. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were BNTX's earnings last quarter?
BNTX's most recent reported quarter was Q1 2026. Net income was $-541M with diluted EPS of $-2.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.